

INHIBITION OF EPIDERMAL GROWTH  
FACTOR-INDUCED ACTIVATION OF  
PHOSPHOLIPASE C BY  
PSI-TECTORIGENIN

Sir:

We have isolated psi-tectorigenin from *No-cardiopsis*, as an inhibitor of phosphatidylinositol turnover (PI turnover). It inhibited epidermal growth factor (EGF)-induced inositol incorporation into inositol lipids with an  $IC_{50}$  of about  $1.0 \mu\text{g/ml}$  in human epidermoid carcinoma A431 cells<sup>1</sup>. We have studied the mechanism of action and found that psi-tectorigenin acts on the activation of phospholipase C, a rate limiting enzyme of PI turnover.


First, we analyzed the effect of psi-tectorigenin on agonist-induced inositol phosphates production. A431 cells ( $3 \times 10^5$ ) grown for 16 hours beforehand in 24-well plates were prelabeled with myo- $[^3\text{H}]$ inositol ( $1 \mu\text{Ci/ml}$ ,  $18.3 \text{ Ci/mmol}$ , Amersham) for 24 hours in inositol-free DULBECCO's modified EAGLE's medium (DMEM) containing 10% dialyzed calf serum. NIH3T3 cells were grown for 2 days before addition of inositol. Then, the medium was removed and the cells were preincubated for 15 minutes in 0.5 ml of inositol-free DMEM containing 30 mM LiCl. Psi-tectorigenin was then added, and after 15 minutes EGF (400 ng/ml) or 20  $\mu\text{M}$  of ATP was added to A431 cells, or bombesin (10  $\mu\text{M}$ ) was added to NIH3T3 cells, and each incubation was continued for a further 5 minutes. The reaction was terminated by the addition of ice-cold 10%  $\text{HClO}_4$ , and the mixture was then neutralized by addition of 1.53 M KOH in 75 mM HEPES. The solution was kept on ice for 15 minutes after which it was centrifuged at 10,000 rpm for 10 minutes at  $4^\circ\text{C}$ . The supernatant was applied to an Amprep SAX column (Amersham), and the column was then washed with water and eluted with 0.17 M  $\text{KHCO}_3$ . The obtained eluate which contains inositol phosphates ( $\text{IP} + \text{IP}_2 + \text{IP}_3$ ) was counted in a liquid scintillation counter. Psi-tectorigenin inhibited EGF-induced inositol phosphates production in a dose-dependent manner and the  $IC_{50}$  value was about  $1.0 \mu\text{g/ml}$ , and complete inhibition was observed at  $30 \mu\text{g/ml}$  (Fig. 1). However, psi-tectorigenin did not inhibit ATP-induced formation of inositol phosphates in A431 cells. It also showed no effect on bombesin-induced inositol phosphates formation in NIH3T3 cells (Fig. 1). Both ATP and bombesin are considered to act by a tyrosine kinase-independent

mechanism<sup>2,3</sup>.

Next we measured the effect of psi-tectorigenin on *in vitro* phospholipase C activity. The assay method was described before<sup>4</sup>. Crude homogenate after removal of nuclear fraction of A431 cells treated with EGF (400 ng/ml) for 10 minutes was used as a phospholipase C preparation. It was incubated with  $[^3\text{H}]$ phosphatidylinositol 4,5-diphosphate ( $[^3\text{H}]\text{PIP}_2$ ) in the presence or absence of various concentrations of psi-tectorigenin at  $37^\circ\text{C}$  for 15 minutes. The reaction was terminated by the addition of 10% TCA and 1% bovine serum albumin. The precipitate was removed by centrifugation, and phospholipase C activity was evaluated by the radioactivity of the TCA soluble fraction containing  $[^3\text{H}]\text{IP}_3$ . Psi-tectorigenin did not affect the activity of phospholipase C up to  $10 \mu\text{g/ml}$ . These results indicated that psi-tectorigenin inhibited phospholipase C indirectly.

Then we looked into the effect of psi-tectorigenin on the activation of phospholipase C. We found that the *in vitro* phospholipase C activity in homogenate

Fig. 1. Effects of agonist-induced inositol phosphate production by psi-tectorigenin in A431 cells or NIH3T3 cells.



After pretreatment of cells with various concentrations of psi-tectorigenin for 15 minutes at  $37^\circ\text{C}$ , EGF (400 ng/ml;  $\circ$ ) or ATP (20  $\mu\text{M}$ ;  $\bullet$ ) was added to A431 cells for 5 minutes. Bombesin (10  $\mu\text{M}$ ;  $\square$ ) was added to NIH3T3 cells. Total inositol phosphates were measured as described in text. The 100% and 0% values (dpm) were  $1,408.7 \pm 16.4$  and  $504.4 \pm 101.5$ ,  $1,281.48 \pm 45.98$  and  $889.15 \pm 40.13$ , and  $2,935.45 \pm 323.94$  and  $1,304.31 \pm 225.38$ , for EGF, ATP and bombesin, respectively. Values are means  $\pm$  SD of triplicate samples.

prepared from EGF-treated A431 cells was 4-fold higher than that from untreated cells, and that EGF failed to activate the enzyme in the presence of psi-tectorigenin (Table 1). Thus, psi-tectorigenin was shown to inhibit the activation step of phospholipase C.


Table 1. Inhibition of EGF-induced phospholipase C (PLC) activation by psi-tectorigenin.

Addition	PLC activity (dpm)
None	332.8 ± 14.2
+ Psi-tectorigenin	547.2 ± 55.0
+ EGF	1338.0 ± 14.2
+ EGF + psi-tectorigenin	609.6 ± 11.5*

A431 cells were treated or not with psi-tectorigenin (25 µg/ml) in the presence of Na<sub>3</sub>VO<sub>4</sub> (100 µM) for 15 minutes, and then EGF (400 ng/ml) was added. After 5 minutes, the cells were collected, homogenized and centrifuged at 500 × *g* for 10 minutes. The phospholipase C activity in the supernatant obtained was determined as described in text. Values are means ± SD of triplicate samples.

\* *P* < 0.02.

Fig. 2. Effect of psi-tectorigenin on tyrosine phosphorylation of EGF receptor.



A431 cells ( $3 \times 10^5$ ) grown for 16 hours beforehand in 35 mm dish were prelabeled for 4 hours with 100 µCi of <sup>32</sup>Pi in phosphate-free DMEM containing 4% dialyzed serum. Psi-tectorigenin was added to cells and preincubated for 15 minutes, then EGF (100 ng/ml) was added. After 5 minutes, the cells were solubilized with 0.5 ml of cold RIPA buffer<sup>6</sup>. Aliquot of cell lysate was incubated with Sepharose-linked anti-phosphotyrosine monoclonal antibody (Oncogene Science, Inc.) at 4°C overnight. Immune complex obtained was electrophoresed on SDS-PAGE. The tyrosine phosphorylated proteins were detected by autoradiography.

Activation of phospholipase C by EGF is considered to involve EGF receptor tyrosine kinase activation<sup>3,5</sup>. In fact, erbstatin, a tyrosine kinase inhibitor, inhibits EGF-induced phospholipase C activation<sup>4</sup>. However, psi-tectorigenin does not inhibit EGF-induced receptor autophosphorylation as detected by EGF receptor antibody<sup>1</sup> and we have confirmed it by using anti-phosphotyrosine antibody (Fig. 2). Psi-tectorigenin at 25 and 50 µg/ml rather increased tyrosine phosphorylation of the receptor slightly. Therefore, psi-tectorigenin should inhibit another process for activation of phospholipase C rather than tyrosine kinase. The mechanism of phospholipase C activation may include a more complex pathway. Psi-tectorigenin may be a suitable tool to elucidate this complex mechanism.

#### Acknowledgment

We would like to thank Dr. S. SHIBAHARA, Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd. for the synthesis of psi-tectorigenin. This work was partly supported by grants from the Ministry of Health and Welfare and the Ministry of Science, Culture and Education of Japan.

MASAYA IMOTO  
NAOMI SHIMURA  
KAZUO UMEZAWA

Department of Applied Chemistry,  
Faculty of Science and Technology,  
Keio University,  
3-14-1 Hiyoshi, Kohoku-ku,  
Yokohama 223, Japan

(Received May 16, 1991)

#### References

- 1) IMOTO, M.; T. YAMASHITA, S. KURASAWA, H. NAGANAWA, T. TAKEUCHI, Z. BAO-QUAN & K. UMEZAWA: Inhibition of cellular phosphatidylinositol turnover by psi-tectorigenin. *FEBS Lett.* 230: 43 ~ 46, 1988
- 2) WAHL, M. I.; S. NISHIBE, P.-G. SUH, S. G. RHEE & G. CARPENTER: Epidermal growth factor stimulates tyrosine phosphorylation of phospholipase C-II independently of receptor internalization and extracellular calcium. *Proc. Natl. Acad. Sci. U.S.A.* 86: 1568 ~ 1572, 1989
- 3) MARGOLIS, B.; S. G. RHEE, S. FELDEN, M. MERVIC, R. LYALL, A. LEVITZKI, A. ULLRICH, A. ZILBERSTEIN & J. SCHLESSINGER: EGF induces tyrosine phosphorylation of phospholipase C-II: A potential mechanism.

- ism for EGF receptor signaling. *Cell* 57: 1101~1107, 1989
- 4) IMOTO, M.; N. SHIMURA, H. UI & K. UMEZAWA: Inhibition of EGF-induced phospholipase C activation in A431 cells by erbstatin, a tyrosine kinase inhibitor. *Biochem. Biophys. Res. Commun.* 173: 208~211, 1990
  - 5) WAHL, M. I.; T. O. DANIEL & G. CARPENTER: Antiphosphotyrosine recovery of phospholipase C activity after EGF treatment of A-431 cells. *Science* 241: 968~970, 1988
  - 6) POIRIER, F.; G. CALOTHY, R. E. KARESS, E. ERIKSON & H. HANAFUSA: Role of p60<sup>src</sup> kinase activity in the induction of neuroretinal cell proliferation by Rous sarcoma virus. *J. Virol.* 42: 780~789, 1982